Mercian Corporation

Eisai R&d Management Co., Ltd.

Nec Platforms, Ltd.

Other

Eisai Company, Limited

Taisho Pharmaceutical Co., Ltd.

Merican Corporation

Takashi Nakashima

Toshio Tsuchida

Kunio Isshiki

Takeo Yoshioka

Mitsuo Nagai

Yoshihiko Kotake

Jun Niijima

Masashi Yoshida

Kazuyuki Dobashi

Tomohiro Sameshima

Yoshio Fukuda

Regina Mikie Kanada

Susumu Takeda

Motoko Matsufuji

Natsuki Hagiwara

Satoshi Yamamoto

Takahiro Iwamoto

Naoto Kawamura

Takashi Sakai

Masahi Yoshida

Takurou Tsuruta

Akifumi Okuda

Tomio Takeuchi

Kiyoshi Okamoto

Yoshiharu Mizui

Toshimitsu Uenaka

Masanori Fujita

Takao Yamori

Naoki Asai

Akira Arisawa

Tomonari Yamada

Asako Kuroda

Hazuki Nagai

Kaname Konuki

Keisuke Komeda

Kumiko Kishi

Masao Iwata

Koji Norihisa

Takashi Adachi

Tomomi Ota

Naoki Matsumoto

Hiroshi Tanaka

Hiroyuki Kumagai

Naoki Agata

Kazuhiro Machida

Tadashi Fujii

Hiroshi Tsunekawa

Yasuhide Aritoku

Katsura Kaneko

Taira Kato

Noriaki Sakata

Kazuya Sakai

Mikie Regina Kanada

A coin placement unit is equipped with: a coin spread portion having two perpendicular wall surfaces and a recessed surface comprising a gutter-shaped recessed portion extending in the direction orthogonal to the perpendicular wall surfaces between the two perpendicular wall surfaces; a coin slot portion having a coin slot; and a ridge line portion provided between the coin spread portion and the coin slot portion so as to partition the coin spread portion and the coin slot portion. The coin spread portion, the ridge line portion, and the coin slot portion have the same width and are continuous in the direction toward a depth side.

Coin placement unit for cash processing machine and self-checkout device including the same

It is an object of this invention to provide a display device capable of easily adjusting the height thereof without providing an extension and contraction mechanism. The display device () of this invention includes: a casing (); and a display unit () to be installed for use onto the casing (), the casing () and the display unit () being available to directly couple to each other. A coupling structure between the casing () and the display unit () is changeable from a state in which the casing () and the display unit () are directly coupled to each other to a state in which the casing () and the display unit () are coupled to each other with a pole () having a columnar shape and separable along a center axis thereof, which is mounted between the casing () and the display unit ().

Display device, and POS terminal device

Provided is a display device, including: a display unit (); a touch panel () stacked on a front part of the display unit (); and a case for housing the touch panel () and the display unit (). The case includes: a rear case (); and a front case () removably attached to the rear case (), which has an opening portion for exposing a touch detection region and a visible region of the touch panel () and the display unit () stacked together. The display unit () is mounted to the rear case (), and the touch panel () is mounted to the front case ().

Display device exhibiting excellent maintainability

The display device includes a display unit including a screen configured to display information; a support column having a tubular shape and being configured to support the display unit at a top end portion of the support column; and a support base configured to support the support column and including a tubular portion that is insertable into and removable from a bottom end portion of the support column. The display device is configured such that the support column is reinserted into the tubular portion of the support base, to thereby enable the screen of the display unit to be faced at a plurality of angles having a tubular axis of the tubular portion as a center.

Display device and POS terminal device

The present invention provides a DNA participating in biological transformation of a macrolide compound 11107B. The present invention provides, particularly, a DNA participating in biological transformation of a macrolide compound 11107B represented by the formula (I) into a 16-position hydroxy macrolide compound 11107D represented by the formula (II), the DNA encoding a protein having 16-position hydroxylating enzymatic activity or ferredoxin, to a method of isolating the DNA, to a protein encoded by the DNA, a plasmid carrying the DNA, a transformant obtained by transforming using the plasmid and a method of producing a 16-position hydroxy compound by using the transformant. 

DNA participating in hydroxylation of macrolide compound

The present invention relates to a compound represented by the formula (I): (wherein, R, R, Rand Rare the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.

Physiologically active substances

The present invention provides a novel method of producing the 12-membered ring macrolide compound 11107D having an antitumor activity by biological transformation. Starting material which is the 12-membered ring macrolide compound 11107B represented by the formula (I) is incubated in the presence of a strain belonging to the genus, the genusor the family Micromonosporaceae (for example,sp. AB-1704 strain (FERM BP-8551)), each of which has the ability of transforming the 12-membered ring macrolide compound 11107B into a 11107D substance represented by the formula (II), or a preparation of its cultured myceha and oxygen, and then 11107D substance which is a target material is collected from the treating solution. 

Method of producing macrolide compound

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it. 

Bioactive substance

Compounds represented by the following general formula (I), pharmacologically acceptable salts thereof or hydrates of the same: (I) wherein W represents and R, R, R, R, R, Rand Rare the same or different and each represents hydrogen, etc. Because of inhibiting angiogenesis and inhibiting the production of VEGF particularly in hypoxia, the compounds (I) are useful as remedies for solid cancer.

The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution ofsp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it

Process for producing isocoumarins and intermediates for the same

Process for producing isocoumarines and intermediates for the same

Growing community of inventors

Kanagawa, Japan

Takashi Nakashima